COST ANALYSIS OF COMMONLY USED DRUGS UNDER PRICE CONTROL IN INDIA: ASSESSING THE EFFECT OF DRUG PRICE CONTROL ORDER ON BRAND PRICE VARIATION
Keywords:
Pharmacoeconomics, Price control, Brands, Price variation, Essential medicinesAbstract
Objective:Â Rising cost of medical therapy is a major concern for patients, and there is high variability in the prices of numerous branded medicines available in India. Drug Price Control Order (DPCO) 2013 was implemented by the government of India with the aim of bringing down the cost of essential medicines. This cost analysis study was carried out to assess the brand price variation in major classes of common drugs under price control; thus assessing the impact of DPCO and analyse issues related to it.
Methods: Latest price list of available brands for cardiovascular drugs, antibacterial, analgesics, drugs for diabetes, asthma, arthritis, convulsions covered under the DPCO, was procured from a leading commercial drug directory. Unit prices of drug formulations available as different brands were compared. Maximum-minimum prices and average prices were found. Price variations between brands were calculated and expressed as percentage variations. Assessment of existing pricing policy and quality norms was done.
Results: Significant inter-brand price variations were found for the majority of formulations. These variations ranged from more than 100 % from average to more than 500 % between maximum and minimum brand prices for drugs like amlodipine, atorvastatin, diclofenac, amoxicillin-clavulanic acid, clopidogrel. Out of 60 formulations observed, 40 showed price variations in excess of 50 % from average price and 23 showed variations greater than 200 % between the costliest and cheapest brands.
Conclusion: Despite the implementation of price control, brand price variations still exist widely for commonly used drugs. Re-assessment of pricing policy and implementation of quality norms is needed.
Keywords: Pharmacoeconomics, Price control, Brands, Price variation, Essential medicines
Downloads
References
Rataboli PV, Garg A. Confusing brand names: the nightmare of medical profession. J Postgrad Med 2005;51:13-6.
Gazette of India–Extraordinary Part II-Sec.3 (ii). Drugs price control order. New Delhi. Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals (National Pharmaceuticals Pricing Authority). Available from: http://www. pharmaceuticals.gov.in/dpco2013gaz.pdf;2013;2:36-67. [Last accessed on 10 Sep 2015].
Compendium of notified ceiling prices of scheduled drugs. National Pharmaceutical Pricing Authority; 2015. Available from: http://www.nppaindia.nic.in. [Last accessed on 27 Jul 2015].
Shrivastava SK. In: Essential drug concept, P-drugs, rational drug therapy, compliance, drug information and pharmacoeconomics. A complete textbook of medical pharmacology. 1st ed. Sirmour HP. Avichal publishing company; 2012. p. 117.
Kumar V, Gupta NV, Kumar AK. A comparison between old and latest systems in DPCO. Int J Pharm Pharm Sci 2014;6:19-20.
Order (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary). New Delhi. Available from: http://www.nppaindia.nic.in/ceiling/press24aug15/so2308e-24-8-15.html. [Last accessed on 01 Aug 2015].
Price Notifications. Order (Published in Part II, Section 3, Sub-Section (ii) of the Gazette of India, Extraordinary). New Delhi. Available from: http://www.nppaindia.nic.in/ceiling/ press13july15/so1894e-13-7-15.html. [Last accessed on 01 Aug 2015].
Price Notifications. Order (Published in Part II, Section 3, Sub-Section (ii) of the Gazette of India, Extraordinary). New Delhi. Available from: http://www.nppaindia.nic.in/ceiling/ press6may15/so1213e-6-5-15.html. [Last accessed on 02 Aug 2015].
Drug pricing policy irrational, re-examine it, Supreme Court tells Centre. [Homepage on the Internet]. New Delhi. The Times of India. Available from: http://timesofindia.indiatimes.com/india/Drug-pricing-policy-irrational-re-examine-it-Supreme-Court-tells-Centre/articleshow/48092107.cms. [Last accessed on 02 Aug 2015].
What’s New. New Delhi. Available from: http://www.nppaindia.nic.in/wh-new-2014/wh-new-44-2014.html. [Last accessed on 03 Aug 2015].
What’s New. New Delhi. Available from: http://www.nppaindia.nic.in/wh-new-2014/wh-new-69-2014.html. [Last accessed on 04 Aug 2015].
Shankar PR, Subish P, Bhandari RB, Mishra P, Saha AC. Ambiguous pricing of topical dermatological products: a survey of brands from two South Asian countries. J Pak Assoc Dermatol 2006;16:134-40.
Price Notifications. Order (Published in Part II, Section 3, Sub-Section (ii) of the Gazette of India, Extraordinary). New Delhi. Available from: http://www.nppaindia.nic.in/paragraph19/press10july14/so1735e-10-7-14.html. [Last accessed on 29 Jul 2015].
Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India 2004;17:80-3.
Trask L. Pharmacoeconomics: Principles, methods, and applications. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: a pathophysiologic approach. 8ed. New York, NY: McGraw-Hill; 2011. Available from: http://accesspharmacy.mhmedical.com/ content.aspx? bookid=462&Sectionid=411007. [Last accessed on 13 Sep 2015].
Karve AV, Chattar KB. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol 2014;3:479-83.
Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci 2013;2:63-9.
Rataboli PV, Dang A. Antimicrobial price variation: conundrum of medical profession! J Postgrad Med 2007;53:72 4.
The world medicines situation. World Health Organization. In: WHO; 2004. Available from: http://www.searo. who.int/linkFiles/Reports_World_Medicines_Situation.pdf. [Last accessed on 04 Aug 2015].
Mohan S, Campbell N, Chockalingam A. Time to effectively address hypertension in India. Indian J Med Res 2013;137:627–31.
Bate R, Zhe JG, Mathur A. Does price reveal poor-quality drugs? Evidence from 17 countries. J Health Economics 2011; 30:1150–63.
Center for Disease Dynamics, Economics and Policy. State of the World’s Antibiotics; 2015. Available from: http://cddep.org/ sites/default/files/swa_2015_final.pdf. [Last accessed on 08 Aug 2015].
Van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010;10:25.
Every third Indian over 18 has high BP. New Delhi. In: The Times of India. Available from: http://timesofindia.indiatimes. com/city/delhi/Every-third-Indian-over-18-has-high-BP/articleshow/49109720.cms. [Last accessed on 27 Sep 2015].
Bhansali A. Cost of diabetes care: prevent diabetes or face catastrophe. J Assoc Physicians India 2013;61:95.
Nair SV, Abdulsalim S, Yedavalli NS, Shukla R, Mohan MK. A prospective study on the average cost of therapy for bronchial asthma patients in an Indian tertiary care teaching hospital. Value Health 2014;17:A594.
Order (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) In: New Delhi. [Last accessed on 01 Aug 2015]. Available from: http://www.nppaindia. nic.in/ ceiling/press26feb15/so619e-26-2-15.html.
Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K. eds. A textbook of clinical pharmacy practice. 1st ed. Himayatnagar, Hyderabad: Orient Longman; 2004. p. 72 3.
Sarkar PK. A rational drug policy. Indian J Med Ethics 2004;1:30 5.
Roy V, Rewari S. Ambiguous drug pricing: a physician’s dilemma. Indian J Pharmacol 1998;30:404 7.
Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics 1992;2:449 55.
Berki SE, Richards JW, Weeks HA. The mysteries of prescription pricing in retail pharmacies. Med Care 1977;15:241 50.
Mamdani B. Drug deals. Indian J Med Ethics 2005;2:63-4.
Calculation of retail price of the formulation. Drug (prices control) policy 1995. In: New Delhi. Available from: http://nppaindia.nic.in. [Last Accessed on 05 Aug 2015].
Schedule M. Good manufacturing practices and requirements of premises, plant and equipment for pharmaceutical products. New Delhi. Available from: http://www.cdsco.nic.in/ writereaddata/ScheduleM(GMP)6.pdf. [Last accessed 06 Aug 2015].
Counterfeit drug incident Encyclopedia. Partnership for safe medicines; c2002-11. Available from: http://www. safemedicines.org/ counterfeit-drug-incident-encyclopedia. html. [Last accessed on 05 Sep 2015].
Medicines: Spurious/falsely-labeled/falsified/counterfeit (SFFC) medicines; c2015. Geneva: World Health Organization; 2012. Available from: http://www.who.int/mediacentre/ factsheets/fs275/en/index.html. [Last accessed on 05 Sep 2015].
Barnes K. New counterfeit report highlights worrying trends. Outsourcing-Pharma. Available from: http://www. outsourcingpharma.com/Contract-Manufacturing/New-counterfeit-report-highlightsworrying-trends. [Last accessed on 06 Sep 2015].
Khan AN, Khar RK. Current scenario of spurious and substandard medicines in India: a systematic review. Indian J Pharm Sci 2015;77:2–7.
Sreeja VN. One more India-based drug manufacturer comes under US Food and Drug Administration (FDA) scrutiny. Available from: http://www.ibtimes.com/one-more-india-based-drug-manufacturer-comes-under-us-food-drug-administration-fda-scrutiny-1285885. [Last accessed 25 Sep 2015].
Government reviews Drug Order 2013 to sort implementation issues. The Economic Times; c2015. Available from: http://articles.economictimes.indiatimes.com/2015-07-26/news/64880505_1_scheduled-formulation-dpco-2013-national-pharmaceutical-pricing-authority. [Last accessed 25 Sep 2015].
Kaiser E. Chhattisgarh deaths: Rat poison in antibiotics. Hindustan times; c2015. Available from: http://www.hindustantimes.com/india-news/c-garh-deaths-rat-poison-in antibiotics/article1-1286247.aspx. [Last accessed on 06 Aug 2015].
Sharma HL, Sharma KK. Pharmacokinetics. In: Principles of pharmacology. 1st ed. Hyderabad, AP: Paras Publishing; 2007. p. 29-30.
Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded–generic medicines of the same manufacturer in India. Ind J Pharmacol 2011;43 Suppl 2:131-6.
Sood R. Generic, drug companies, fleecing patients. The Tribune, Chandigarh, India, Himachal Plus; 2010. Available from: http://www.tribuneindia.com/2010/20100210/ himplus.htm#1. [Last accessed on 13 Jan 2010].
Kotwani A. Will generic drug stores improve access to essential medicines for the poor in India? J Public Health Policy 2010;31:178–84.
Francis PA. Revision of NLEM needed; c2015. Available from: http://www.pharmabiz.com/ArticleDetails.aspx?aid=85572&sid=3. [Last accessed on 15 Sep 2015].
Nagarajan R. 80 % of medicines not covered by price control order. Times of India; c2015. Available from http://timesofindia.indiatimes.com/india/80-of-medicines-not-covered-by-price-control-order/articleshow/26678324.cms. [Last accessed on 25 Aug 2015].
Basavaraj S, Betageri GV. Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges. Acta Pharm Sinica B 2014;4:3-17.
Subbu R. editors. Pricing row hits pharma industry. New Delhi. The Hindu. Available from: http://www.thehindu. com/business/ Industry/pricing-row-hits-pharma-industry/ article6453089.ece. [Last accessed on 28 Aug 2015].
New Delhi. Available from: http://www.nppaindia.nic.in/ order/withdrawguideline-22-9-14.pdf. [Last accessed on 02 Sep 2015].
Shrank WH, Porter ME, Jain SH, Choudhry NK. A blueprint for pharmacy benefits managers to increase value. Am J Managed Care 2009;15:87–93.
Frazier LM, Brown JJ, Divine GW. Can physician education lower the cost of prescription drugs? A prospective controlled trial. Ann Intern Med 1991;115:116-21